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Mohamad Shariff A Hamid1,2*, Mohamed Razif Mohamed Ali1†, Ashril Yusof3† and John George4†Abstract
Background: Muscle injuries are one of the commonest injuries affecting athletes. It often leads to significant pain
and disability causing loss of training and competition time. With current treatment, the duration to return-to-play
ranges form six weeks to never, depending on injury severity. Recent researches have suggested that autologous
platelet-rich plasma (PRP) injection into the injured site may hasten soft tissues healing. To-date, there has been no
randomised clinical trials to evaluate the effects of PRP on muscle healing. The aim of this study is to examine the
effects of autologous PRP on duration to return-to-play after muscle injury.
Methods and design: A randomised, single blind controlled trial will be conducted. Twenty-eight patients aged
18 years and above with a recent grade-2 hamstring injury will be invited to take part. Participants will be
randomised to receive either autologous PRP injection with rehabilitation programme, or rehabilitation programme
only. Participants will be followed up at day three of study and then weekly for 16 weeks. At each follow up visit,
participants will be assessed on readiness to return-to-play using a set of criteria. The primary end-point is when
participants have fulfilled the return-to-play criteria or end of 16 weeks.
The main outcome measure of this study is the duration to return-to-play after injury.
Conclusion: This study protocol proposes a rigorous and potential significant evaluation of PRP use for grade-2
hamstring injury. If proven effective such findings could be of great benefit for patients with similar injuries.
Trial registration: Current Controlled Trials ISCRTN66528592Background
Muscle injuries are one of the commonest injuries affect-
ing athletes [1]. They account for up to 30 – 50% of the in-
juries in sports events [2,3]. Majority of muscle injuries
are results of excessive strain on muscle, which occurs
during sprinting or jumping. Muscle injury may be the re-
sult of excessive eccentric contraction, when the muscle
develops tension while lengthening [4]. This injury often
affects the myotendinous junction of superficial muscles
spanning across two joints, such as the rectus femoris,
semitendinosus, and gastrocnemius muscles [1].* Correspondence: ayip@um.edu.my
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reproduction in any medium, provided the orThe diagnosis and grading of muscle injury is usually
made through a thorough clinical assessment. Diagnostic
ultrasound examination is often recommended as the
method of choice for confirming and grading the muscle
injury [5]. Despite the high frequency of muscle injury, the
best method of its treatment has not yet been clearly
defined. Currently, many interventions are used, guided by
limited randomised controlled trials and quality prospect-
ive studies [6]. In professional sports, muscle injury often
leads to significant pain and disability causing loss of train-
ing and competition time. Despite many treatment
options, the duration of the return-to-play (RTP) period
ranges from six weeks to never, based on the severity of
the strains [7]. Current treatment includes rest, ice, com-
pression and elevation (RICE) with a short period of
immobilization during the early phase. In addition, short-
term use of nonsteroidal anti-inflammatory (NSAIDs),al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is recommended [6,8-14].
Basic science of muscle healing has directed attention
towards the use of autologous biological products as a
treatment alternative for muscle injury. Damaged muscle
goes through the early phase of destruction (inflamma-
tory phase), where affected cells including muscles,
blood vessels, connective tissues and intramuscular
nerve undergo necrosis [15]. This phase is followed by
repair and remodelling phases, in which undifferentiated
satellite cells, in response to various growth factors, pro-
liferate and differentiate into mature myoblasts in an ef-
fort to replace the injured muscle fibers [1]. Many of the
growth factors are stored in the alpha (α) granules
within platelets [16].
Inflammation occurring after muscle injury usually
leads to accumulation of inflammatory cells, neutrophils
and macrophages. Activation of platelets also occurs
early at the injured site. Activated platelets degranulate
releasing various substances, including growth factors.
In addition, platelets contain other metabolically active
substances such as adhesive proteins (TSP-1), clotting
factors and their inhibitors (TFPI), proteases (MMP-1, 2
& 9 and TIMP1-4), chemokines (SDF-1α), cytokines and
membrane glycoproteins (CD40L), involved in tissue re-
pair and regeneration [16]. Platelet derived growth fac-
tors (PDGF), vascular endothelial growth factors
(VEGF), epidermal growth factor (EGF), basic fibroblasts
growth factors (bFGF), insulin-like growth factor-1
(IGF-1) and transforming growth factor beta-1 (TGF-β1)
are some of the growth factors released by platelets [17].
IGF-1 and bFGF have the ability to accelerate healing
following muscle and tendon injury [18]. A previous
study from an animal model showed autologous PRP in-
jection significantly hastens tibialis anterior muscle re-
covery from 21 days to 14 days [19]. Sanchez et al. at the
2nd World Congress on Regenerative Medicine 2005
presented a similar finding. They noted athletes receiv-
ing PRP injection under ultrasound guidance gain full
recovery within half of the expected time [20]. In a study
involving professional athletes, Wright-Carpenter et al.
(2004) demonstrated autologous conditioned serum
(ACS) injected into the injured muscle shortened the
duration to full RTP by 30% (six days). They attributed
the observed effects to the presence of increased levels
of growth factors (FGF-2, HGF and TGF-β1) demon-
strable on ELISA [7]. In 2010, the International Olympic
Committee (IOC) concluded that currently there is very
limited scientific evidence of clinical efficacy and safety
profile of PRP use in athletic injuries [21]. More re-
cently, a systematic review article, reported there has
been no randomised clinical trials of PRP effects on
muscle healing. In addition, only four clinical reports
(level of evidence 3 or 4) were available [22]. More workon clinical science of PRP using robust clinical trials to
demonstrate its efficacy has been recommended [21,22].
This paper describes the protocol of a randomised con-
trolled trial to evaluate the clinical efficacy of a single in-
jection of PRP combined with a rehabilitation programme
on the duration to RTP after grade-2 hamstring injury.
We hypothesized that distinct differences would be
observed in the duration of RTP between those treated
with combined PRP and rehabilitation programme versus
rehabilitation programme alone. The presence of various
growth factors in PRP could speed up muscle recovery.
Methods and design
Study design
This study involved a randomised, assessor-blinded con-
trolled trial of 16-week duration. Participants were
screened before enrolment. Measurements (described
below) were taken upon study enrolment. On day three
following the PRP injection, the participants were reviewed
for any adverse reaction. Subsequently, all the participants
were reassessed once a week until the end of the study
period. The protocol conformed to the CONSORT guide-
lines for nonpharmacological interventions [23].
Participants
Patients with confirmed grade-2 hamstring muscle injury
were invited to participate in this study. Study notice and
invitation to take part were distributed to all sports physi-
cians practicing within Klang Valley, Selangor, Malaysia.
The eligibility criteria for inclusion were as follows:
(i) Aged ≥ 18 years;
(ii) Acute hamstring muscle injury (≤ seven days);
(iii)Able to understand study protocol and completing
the written informed consent.
The exclusion criteria were:
(i) Having received any form of injection therapy for
current injury;
(ii) Using nonsteroidal anti-inflammatory drugs
(NSAIDs) within one week before randomisation;
(iii)Unable to fulfil follow-up;
(iv) Significant cardiovascular, renal, hepatic disease,
malignancy, history of anaemia, and previous
muscle surgery.
Procedure
The procedure is outlined in Figure 1. An initial screening
was conducted at the Sports Medicine Clinic of the Uni-
versity of Malaya Medical Centre to determine injury se-
verity. A sport physician and a physiotherapist conducted
physical examination and grading of injury severity using
Figure 1 Summary of trial design.
Table 1 Grading of muscle strain injuries on ultrasound
Grade Ultrasound findings
0 No ultrasound features seen
1 Muscle oedema only
2a Partial tears of muscle fibres, disruption involving <33%
2b Partial tears of muscle fibres, disruption involving≥ 33 – 66%
2c Partial tears of muscle fibres, disruption involving≥ 66 - 99%
3 Complete tear of muscle
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DeLee et al. [24,25].
Later, two experienced musculoskeletal radiologists
conducted a diagnostic ultrasound (Philips IU 22 ultra-
sound with 17–5 MHz Probe) to confirm the diagnosis,
using the grading system used at our hospital (Table 1)
and the grading suggested by Peetrons et al. [26]. Any
disagreement between assessors was resolved through
discussion. Diagnostic ultrasound assessment was con-
ducted 24 to 48 hours after completion of physical
examination. We also kept the record of those found to
be ineligible. Patients with grade-2 hamstring muscle in-
jury on clinical assessment and confirmed on diagnostic
ultrasound examination were invited to participate.Randomisation
Participants were randomly allocated into one of two
groups: (i) autologous PRP group or (ii) control group.
Randomisation was performed on those eligible after
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puter generated block randomisation of four was used to
create a randomisation schedule. Treatment assignments
were conducted by the trial manager MS.Blinding
Three physiotherapists (PC, FJ, SR) acted as the outcome
measure assessors. They were involved in providing
standard rehabilitation programmes to all participants
but were blinded about the participant group allocation.
The participants were requested not to disclose details
of their treatment. On trial completion, the assessor was
asked to guess which treatment each participant
received. The success of blinding was determined by cal-
culating the ‘blinding index’ using the method demon-
strated by James et al. [27].Interventions
PRP intervention group
Participants in the PRP group received a single injection
of autologous PRP under expert ultrasound guidance by
a musculoskeletal radiologists trained in interventional
musculoskeletal injections. The injection was adminis-
tered once, following randomisation of the treatment
group (day 1 of the study).PRP preparation
Fifty-five millilitres (ml) of venous blood were col-
lected from the participants’ arm into a 60 ml syringe
primed with ACD-A. In addition, 2 ml of venous
blood were collected and sent to the hospital labora-
tory for determination of platelets and leucocytes
count. The blood collected for PRP was prepared
according to the GPSTM III Systems instruction for
use (Biomet Biologics, Inc., Warsaw, Ind). Since an
acidic anticoagulant was added during the collection
of whole blood, PRP was buffered to increase the pH
to normal physiological levels. This was accomplished
by adding 8.4% sodium bicarbonate solution in a ratio
0.05 ml of sodium bicarbonate to 1 ml of PRP. No
activating agent was added to the PRP. The time
taken to prepare PRP was about 30 minutes. A standard
60 ml GPSTM III kit could produce approximately 6 ml
of PRP.
In our study, 3 ml of extracted PRP were injected
into the injured area under ultrasound guidance. One
ml was sent to the hospital laboratory for platelets and
leucocyte count, while the remaining 2 ml were stored
in −20° Celsius for analysis of growth factors (basic
fibroblast growth factor [bFGF]; insulin-like growth
factor-1 [IGF-1]; transforming growth factor-β1 [TGF-β1]),
which were done later.Injection technique
As a recent study showed, a statistically significant de-
crease in tenocyte proliferation and cell viability, follow-
ing PRP combined with the local anaesthetic agent
(lidocaine and bupivacaine) [28], no local anaesthetic
was given prior to PRP injection in the current study.
To the best of our knowledge the current existing
guideline lacks information on the optimal timing, fre-
quency of administration, clinical effective dose and vol-
ume, as well as post-injection rehabilitation technique
following PRP injection for muscle injury [21,29]. Fur-
thermore, no long-term clinical studies exist on potential
adverse effects. Our decision to use a single injection of
3 ml of PRP in the intervention group was based on the
findings of existing clinical studies. Sanchez at al.
reported ultrasound guided injection of autologous prep-
aration rich in growth factors (PRGF) within the injured
muscle enhances healing and functional recovery. Fur-
ther, small tears indicated good progress with a single ap-
plication of PRGF, while a medium to large size tears
required two or three applications of PGRF [20]. Hamil-
ton et al. reported single injection of PRP combined with
daily physiotherapy programme was effective for grade II
semimembranosus strain injury. They demonstrated
17 days following injection of 3 ml PRP, the athlete was
pain free and able to achieve full range of motion. The
athletes were back to their preinjury activities after
3 weeks [30].
Under ultrasound guidance, 3 ml of PRP were injected
directly into the injured area via an 18 G needle using a
peppering technique. All injections were done under
aseptic technique. Each participant in the PRP combined
rehabilitation programme group received a single injec-
tion of PRP throughout the study. Immediately after in-
jection, the patient was kept in supine position for 10 to
15 minutes. Participants were advised to rest, limit their
activities for the next 48 hours, and use only acetamino-
phen for pain. The use of non-steroidal medication was
prohibited.
Participants were reassessed for any adverse reaction
three days after receiving PRP. Later, weekly reassess-
ment was conducted until the end of the study. All par-
ticipants were asked to continue with an unsupervised
daily home exercise programmes as prescribed and to
keep a record of these sessions. The use of painkillers,
other than nonsteroidal anti-inflammatory drugs, was
allowed. All medication use was recorded.
Participants in both groups were required to attend a
weekly rehabilitation session with a physiotherapist until
full recovery or the end of 16 weeks. At each visit, out-
come measures were assessed, and rehabilitation pro-
grammes were conducted under a physiotherapist’s
supervision. Each treatment session lasted for 45 – 60
minutes. Three-experienced physiotherapists (with at
Table 2 Rehabilitation programme
Phase 1
1. Low to moderate-intensity sidestepping, 3 × 1 min
2. Low to moderate-intensity grapevine stepping (lateral stepping with
the trail leg going over the lead leg and then under the leg), both
directions, 3 × 1 min
3. Low to moderate-intensity steps forward and backward over a tape
line while moving sideways, 2 × 1 min
4. Single-leg stand progressing from eyes open to eyes closed 4×20 sec
5. Prone abdominal body bridge (performed by using abdominal and
hip muscle to hold the body face-down straight-plank position with
the elbows and feet as the only point of contact), 4 × 20 sec
6. Supine extension bridge (performed by using abdominal and hip
muscles to hold the body in a supine hook lying position with the
head, upper back, arms, and feet as the points of contact), 4 × 20 sec
7. Side bridge, 4 × 20 sec on each side
8. Ice in long-sitting position for 20 min
Phase 2*
1. Moderate to high-intensity sidestepping, 3 × 1 min
2. Moderate to high-intensity grapevine stepping, 3 × 1 min
3. Moderate to high-intensity steps forward and backward while
moving sideways, 2 × 1 min
4. Single-leg stand windmill touches, 4 × 20 sec of repetitive alternate
hand touches
5. Push-up stabilization with trunk rotation (performed by starting at
the top of a full push-up, then maintain this position with 1 hand
while rotating the chest toward the side of the hand that is being
lifted to point toward the ceiling, pause and return to the starting
position), 2 × 15 reps on each side
6. Fast feet in place (performed by jogging in place with increasing
velocity, picking the foot only a few inches off the ground),
4 × 20 sec
7. Proprioceptive neuromuscular facilitation trunk pull-downs with
Thera-Band, 2 × 15 to the right and left
8. Symptom-free practice without high-speed manoeuvres
9. Ice for 20 min if any symptoms of local fatigue or discomfort present
Key: Low intensity, a velocity of movement that is less than or near that of
normal walking; moderate intensity, a velocity of movement greater than
normal walking but not as great as sport; high intensity, a velocity of
movement similar to sport activity.
* Participants allowed to progress from phase 1 to phase 2 when they could
walk with a normal gait pattern and perform a high knee march in place
without pain.
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versity Malaya Medical Centre and National Institute of
Sports were trained to assess outcome measures and de-
liver rehabilitation programmes. The training involved a
half-day course delivered by the principal researcher and
a treatment manual. The treatment manual contained a
brief summary of the study, assessment methods and
hamstring rehabilitation based on the programme used
by Sherry et al. [31]. In addition, the participants were
expected to independently track their exercise compli-
ance by recording the days they performed the pre-
scribed rehabilitation programme on a logbook and to
report any difficulties at each follow-up visit. The re-
habilitation programme used in the study focused on
progressive agility and trunk stabilization exercises
(Table 2). This programme was based on a set of exer-
cises used in an earlier study [31]. Further, this
programme was found to be more effective than a
programme that only emphasized on hamstring stretch-
ing and strengthening in promoting RTP and preventing
injury recurrence in athletes affected with an acute ham-
string strain [31].
Primary outcome measures
In this study, primary outcome was the duration of RTP.
Duration of RTP is defined as the duration (days) from
the date of injury until the participants fulfil the criteria
for RTP. The decision on determination of fitness for
RTP is based on expert opinion [32]. As there were lim-
ited scientific studies done to examine the outcome of
various RTP strategies [33], we decided to come up with
our own criteria of RTP (Table 3) based on recent clin-
ical sports medicine recommendations [8,34-37].
Direct hamstring palpation was conducted and pain
elicited was recorded in the participants’ clinical research
form (CRF). Pain provocation test was evaluated by iso-
metric contraction of the hamstring muscles when palpa-
tion did not elicit any tenderness. This test was
performed in prone lying with the knee flexed at approxi-
mately 15° [38]. Hamstring range of movement (ROM)
was assessed using the active knee extension (AKE) test.
The AKE test involves movement of the knee joint but
not the hip, unlike the straight-leg raise (SLR) test which
involves movements of both hip and knee joints. AKE
test is an active test and is considered safe as the partici-
pants dictate the end point. This test has been recom-
mended and often used to measure hamstring tightness.
AKE test normal values of knee motion were reported to
be within 20° on full extension of the knee [39].
Hamstring muscle strength was assessed using an iso-
kinetic dynamometer (System 4 Pro, Biodex Medical
System, NY, USA). Assessment of hamstring and quadri-
ceps muscles of both legs was also conducted during
participants’ weekly visit. Participants were allowed tofamiliarise with the experimental protocol before testing.
During the familiarization period, participants practiced
with sub-maximal effort. The participants’ knee joint
centre was kept aligned with the axis of the dynamom-
eter crank arm. The testing protocol included maximum
voluntary strength of both legs, with the uninjured leg
tested first. Muscle strength test was performed under
concentric exertion at three angular speeds (60°, 180°
and 240°/second). Each participant performed five max-
imum contractions at angular speeds of 60°/s, ten max-
imum contractions at angular speeds of 180°/s, and
fifteen maximal contractions at angular speeds of 240°/s,
with a rest interval of about 60 seconds between each
Table 3 Criteria for return-to-play (RTP)
Sign General Recommendation
Pain Pain-free (on direct palpation)
Pain free on hamstring contraction (resisted isometric
hamstring muscle contraction)
Range of motion Symmetrical with unaffected site
Strength Isokinetic strength within 5% [29,30]
to 10% [8] of contralateral side
A Hamid et al. BMC Musculoskeletal Disorders 2012, 13:138 Page 6 of 8
http://www.biomedcentral.com/1471-2474/13/138speed. At each speed, quadriceps muscles were tested
first followed by the hamstrings. The participants did
not receive any visual feedback during the test; however,
verbal encouragements were given.
The participants that failed to meet the RTP criteria at
the end of week 16 were allowed to continue their treat-
ment in the UMMC until full recovery.
Secondary outcome measures
The Brief Pain Inventory - Short Form (BPI-SF) ques-
tionnaire were used to assess the severity and impact of
pain on the participants’ daily functions. The BPI-SF is a
self-reported questionnaire. It consists of four questions
related to pain severity and seven questions related to
pain interference on daily functions. The pain intensity
items are presented as numeric rating scales, with a
minimum score of 0 (indicating no pain) and a max-
imum score of 10 (when pain is as bad as one could im-
agine). Similar scales are used for the seven items on
interference of participants’ daily functions. The BPI-SF
has been validated in several languages, including Malay
[40] and demonstrated a Cronbach alpha reliability that
ranges from 0.77 to 0.91 [41].
Platelet levels in participants’ venous blood and PRP
were determined. In addition, levels of insulin-like
growth factor-1 (IGF-1), basic fibroblasts growth factor
(bFGF) and transforming growth factor-beta 1 (TGF-β1)
were determined using ELISA kits (Cusabio, USA).
The participants’ attendances to the physiotherapy session
were recorded to determine adherence. In addition, their
daily logbook of self-home exercise was also evaluated.
Any adverse events occurring during the study were
documented and proper measures were taken.
Sample size
Sample size was determined using the following formula
[42]:




N= the sample size in each of the groups
zð1α=2Þ of :05= 1.96 (percentage of the normal
distribution for statistical significance level of .05)zð1βÞ of80%= .84 (percentage of the normal
distribution for statistical power of 80%)
μ1 = population mean in treatment Group 1
μ2 = population mean in treatment Group 2
μ1 – μ2 = the mean difference
σ2 = population [standard deviation (SD)]
Total sample size after estimation of 30% attrition rate
= 11 + 3 = 14 participants in each intervention group
giving a total of 28 participants altogether [7].
Data and statistical analysis
The primary analysis was done using the principle of
intention-to-treat (ITT). ITT analysis includes partici-
pants with incomplete data, those who deviated from
the study protocol and those who withdrew from the
study. Missing data were handled through multiple im-
putation methods [43].
Socio-demographic, clinical characteristics and base-
line information were presented to assess comparability
between groups. Similar variables were also examined
among the participants who withdrew from the study.
The primary endpoint of the study was the date when
RTP was achieved or the end of week 16. Differences for
categorical variables are tested with a chi-square test or
Fischer’s exact test. As clinical outcome variables were
repeatedly measured over time, a multivariate analysis of
variance (MANOVA) for repeated measures was per-
formed to explore an overall time, general group, and
the time by group interaction effect.
Signs and symptoms changes were explored using lin-
ear regression analysis to determine the rate of change.
In addition, levels of the various growth factors (IGF-1,
bFGF and TGF) were determined. Statistical analyses
were carried out using SPSS (Version 19). For all ana-
lyses, a value of P <.05 was considered significant.
Timelines
The study was approved by the University Malaya Medical
Centre (UMMC), Medical Ethics Committee in February
2011 (MEC Ref. No: 835.11). Recruitment and training of
physiotherapists were conducted in September 2011. Pa-
tient recruitment started from February 2012. Expected
completion date of the study is in December 2012.
Discussion
This is the first randomised controls study to examine
the effect of PRP on duration of RTP after a grade-2
hamstrings injury. There are several major strengths of
the intervention design in this study. The primary out-
come of this study includes a combination of subjective
and objective assessments of RTP criteria. The criteria
used are based on several current recommendations
from leading experts and reflect present clinical practice
[8,34-37].
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based on a contemporary programme that was effective
for acute hamstring strain. The average (±SD) time
needed to RTP in athletes under such a rehabilitation
programme was 37.4 ± 27.6 days [31].
Grade-2 muscle injury is confirmed on ultrasound
(US) assessment. US is a cheap, reproducible and well-
tolerated imaging examination, which also provides a
real-time functional assessment in multiplanar views
[44]. US is suggested to have equal sensitivity to MRI for
acute hamstring muscle complex injury, especially when
performed within 2 weeks following injury [45]. US as-
sessment of hamstring injury in our study would ensure
uniformity of injury grading and allow comparison of
treatment interventions between groups.
Infiltration of autologous PRP under ultrasound guid-
ance allows accurate delivery of PRP contents to the site
where it is to have the greatest effect [46].Finally, levels
of growth factors including IGF-1, bFGF and TGF-β1 in
the PRP are determined using ELISA kits. This would
allow us to explore the potential individual effect of PRP
constituents on muscle healing.
Conclusion
This is a randomised controlled trial exploring the ef-
fectiveness of a single injection of autologous PRP com-
bined with hamstring rehabilitation programme on the
duration of RTP after a grade-2 hamstring injury. The
major strengths of this study include reproducibility and
reflection of current clinical management of grade-2
hamstring injury. The findings enable recommendations
of this treatment alternative for grade-2 hamstring
injury.
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